Overview
Eligible centres can access funded pTau217 testing for patients with suspected early Alzheimer’s disease. Complete the ICL intake form to set up your account and choose your preferred test method.
pTau217
Plasma p-tau217 is a blood-based biomarker that reflects abnormal tau phosphorylation, a process linked to Alzheimer’s disease (AD) pathology and often associated with amyloid-β accumulation in the brain.1 Elevated plasma levels of p-tau217 are observed in individuals with both amyloid-β and tau pathology, supporting its utility as a biomarker for early biological changes in AD.1
Two Methods Available
You’ll indicate your preferred method on the intake form below when setting up your account.
Patient Eligibility
- To diagnose or rule out AD in patients suspected to have early symptomatic AD.
- Cognitive criteria: patients must present with subjective cognitive impairment, mild cognitive impairment (amnestic or non-amnestic), or dementia.
- This test is not suitable for patients who have had a blood transfusion within 2–4 weeks, or who have had an allogeneic bone marrow transplant.
Getting Started
1. Account Setup
Complete the online ICL intake form below.
2. Logistics
ICL will contact you to review collection and shipping options. Your confirmed collection location and shipping instructions will be printed on the requisitions patients receive.
3. Ordering
A brief virtual kick-off to deliver your custom requisitions and walk through ordering, shipping and reporting. Funding covers a set number of tests per site; ICL will notify you as you approach your limit.
4. Results
Results are reported through ICL’s online portal, which you will have access to once your account is set up.
Program Terms
ICL will provide participating centres with a limited number of unique requisition forms. This program may be cancelled at any time.
Questions or Support
Email: JefferyCuneo@iclabs.ca
Phone: 416-422-3000 ext. 300
About ICL
In-Common Laboratories (ICL) is a Canadian not-for-profit lab referral service that connects hospitals and clinicians with a trusted network of accredited labs across more than 10 provinces and territories. ICL manages every step of referral testing, from specimen logistics to reporting and billing. ICL is accredited by Accreditation Canada and certified to ISO 15189 Plus™ and ISO 27001:2022. Backed by advanced security technology and SOC 2 certification, we uphold the highest standards for data protection, privacy, and operational integrity. ICL offers a full catalogue of specialized testing with no order minimums. Because we’re not-for-profit, every referral helps keep health care dollars in Canada’s public system. Learn more.
- Mintun MA, Lo AC, Duggan Evans C, et al. N Engl J Med. 2021;384(18):1691–1704.
This program is funded by Eli Lilly Canada Inc. CMAT-60504